NKTX
Nkarta, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.92
+4.66%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +2.0%
- EBIT
- -2.9%
- EPS
- -6.1%
- Free cash flow
- +6.3%
- Operating cash flow
- +5.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -2.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +4.8%
- EBIT
- +5.5%
- Net income
- +4.3%
- EPS
- +11.9%
- Free cash flow
- +13.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026